BNI Revolutionaries

Agenus Inc. is a pioneering biotechnology company based in Lexington, Massachusetts, dedicated to harnessing the power of the immune system to develop innovative therapies aimed at curing cancer. With a focus on immuno-oncology, the company is advancing a diverse pipeline of therapeutic candidates designed to enhance treatment efficacy and tolerability for patients with challenging tumors. Through strategic partnerships and a commitment to research, Agenus is expanding access to immuno-oncology therapies while optimizing combination approaches that leverage antibody therapeutics and adoptive cell therapies. Their flagship program, botensilimab, is a next-generation CTLA-4 antibody aimed at improving treatment outcomes for patients with both cold and hot tumors. Generated from the website